Autologous HSCT for advanced MS: Is the glass half-empty or really half-full? [1]

Brain

Volumn 131, Issue 2, 2008, Pages

  Nash, Richard A ^a,f   Stuve, Olaf ^b   Bowen, James D ^c   Frohman, Elliot M ^b   Griffith, Linda M ^d   Hutton, George J ^e   Kraft, George H ^f   Popat, Uday ^g   Racke, Michael K ^h   Muraro, Paolo A ⁱ  

^a USA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Evergreen Hospital Medical Center   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB;

AUTOPSY; BRAIN DAMAGE; DEMENTIA; DEMYELINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

AUTOPSY; AXONS; BIOPSY; BRAIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; TREATMENT FAILURE;

EID: 38849177483     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm180     Document Type: Letter

References (5)

1. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108.
2. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-12.
3. Martin R. Is haematopoietic stem cell transplantation a treatment option for severe MS or not? Brain 2007; 130: 1181-2.
4. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 2007; 130: 1254-62.
5. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. New Engl J Med 1998; 338: 278-85.